Buy Lapatinib 250 mg online, Buy Tykerb 250 online, Buy Tyverb online.

Lapacent (Lapatinib) 250 mg by Incepta Pharma is used to treat certain type of breast cancer (HER2-positive). It works by slowing the growth of cancer cells.

Lapacent is the alternative & generic version of Tykerb/Tyverb by GlaxoSmithKline. Lapacent is manufactured by Incepta Pharmaceuticals Bangladesh which is the biggest pharmaceutical company in Bangladesh.

Therapeutic Class

Cytotoxic Chemotherapy

Pharmacology

Lapatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor of both Epidermal Growth Factor Receptor (EGFR [ErbB1]) and Human Epidermal Receptor Type 2 (HER2 [ErbB2]) receptors.

It blocks the phosphorylation and activation of downstream 2nd messengers (Erk1/2 and Akt) which regulate cellular proliferation and survival of ErbB- and ErbB2-expressing tumours.

Dosage

The recommended dosage of tykerb for advanced or metastatic breast cancer is 1,250 mg (5 tablets) given orally once daily on Days 1-21 continuously in combination with capecitabine 2,000 mg/m2/day (administered orally in 2 doses approximately 12 hours apart) on Days 1-14 in a repeating 21 day cycle.

The recommended dose of Lapatinib for hormone receptor positive, HER2 positive metastatic breast cancer is 1500 mg (6 tablets) given orally once daily continuously in combination with letrozole. When Lapatinib is coadministered with letrozole, the recommended dose of letrozole is 2.5 mg once daily.

tykerb should be taken at least one hour before or one hour after a meal. However, capecitabine should be taken with food or within 30 minutes after food.

tykerb should be taken once daily. Do not divide daily doses of tykerb. Modify dose for cardiac and other toxicities, severe hepatic impairment, and CYP3A4 drug interactions.

Administration

Should be taken on an empty stomach. Take at least 1 hr before or 1 hr after a meal. Do not eat/drink grapefruit products.

Interaction

Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist.

This medication can slow down the removal of other medications from your body, which may affect how they work. Examples of affected drugs include certain “statin” cholesterol medications.

Other medications can affect the removal of tykerb from your body, which may affect how lapatinib works. Examples include dexamethasone, cimetidine, St. John’s wort, azole antifungals (such as itraconazole, ketoconazole),

macrolide antibiotics (such as erythromycin, clarithromycin), HIV protease inhibitors (such as ritonavir, saquinavir), rifamycins (such as rifabutin), certain anti-seizure medicines (such as phenytoin), among others.

Many drugs besides tykerb may affect the heart rhythm (QT prolongation), including dofetilide, pimozide, procainamide, amiodarone, quinidine, sotalol, macrolide antibiotics (such as erythromycin), among others. Therefore, before using tykerb.

Contraindications

Contraindicated to hypersensitivity to any other ingredient of this product.

Side Effects

GI disturbances, dermatological reactions (e.g. palmar-plantar erythrodysesthesia, rash), fatigue, decreases in LVEF, QT interval prolongation, stomatitis, mucosal inflammation, pain in extremities, back pain, dyspnoea, insomnia, epistaxis, alopecia, nail disorders (e.g. paronychia).

Pregnancy & Lactation

Pregnancy category D. There is positive evidence of human foetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).

Precautions & Warnings

Patient with hypokalaemia or hypomagnesaemia, congenital QT prolongation. Severe hepatic impairment. Pregnancy and lactation.

Use in Special Populations

Patient on potent CYP3A4 inhibitor-

• HER2 overexpressing advanced or metastatic breast cancer: Increase gradually from 1.25 g daily up to 4.5 g daily.

• HER2 overexpressing hormone receptor positive metastatic breast cancer: Increase gradually from 1.5 g daily up to 5.5 g daily.

Hepatic Impairment (Severe)-

• HER2 overexpressing advanced or metastatic breast cancer: 750 mg once daily.

• HER2 overexpressing hormone receptor positive metastatic breast cancer: 1 g once daily.

Storage Conditions

Store between 15-30° C.